Commitments and Contingencies

12 Months Ended

Dec. 31, 2016

Commitments And Contingencies Disclosure [Abstract]

Note 10. Commitments and Contingencies

In September 2015, the Company entered into a lease agreement for approximately 22,000 square feet of office space in San Francisco, California, which serves as its corporate headquarters. The initial term commenced in February 2016 and expires in June 2022 with total payments due of $10.2 million. In November 2016, the Company entered into an amendment to this lease agreement which provided it with approximately 8,000 additional square feet and extended the term of the lease for an additional 12 months, through to June 2023. The total minimum lease payments due for this lease aggregate $15.0 million.

In July 2015, the Company entered into a sub-lease agreement for approximately 22,000 square feet of manufacturing space in South San Francisco, California for an initial term that expires in May 2017 with total minimum lease payments due of $0.9 million. In November 2015, the Company purchased an option that was subsequently exercised in May 2016 to enter into a ten-year lease for the existing 22,000 square feet plus approximately 17,000 additional square feet of manufacturing space, which will become effective in June 2017. The total minimum lease payments related to this extension aggregate $7.3 million.

In April 2016, the Company entered into a sublease agreement with TerraVia, Inc., formerly Solazyme, Inc., to sublease approximately 8,983 square feet of research and development laboratory space in South San Francisco, California with total minimum lease payments of $0.6 million over an approximately two-year term.

As of December 31, 2016, future minimum lease payments under non-cancelable operating leases are as follows:

	Amount
	(in thousands)
2017	$	2,831
2018		2,928
2019		2,983
2020		3,071
2021		3,162
Thereafter		7,747
Total minimum lease payments	$	22,722

Guarantees and Indemnifications

The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company’s request in such capacity, as permitted under Delaware law, and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity. The maximum amount of future indemnification is unlimited; however, the Company currently holds director liability insurance. This insurance allows the transfer of risk associated with the company’s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has not recognized any liabilities relating to these obligations for any period presented.